Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

por Schauer, Stephen P., Mylott, William R., Yuan, Moucun, Jenkins, Rand G., Rodney Mathews, W., Honigberg, Lee A., Wildsmith, Kristin R.
Publicado 2018

Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics

por Wildsmith, Kristin R, Schauer, Stephen P, Smith, Ashley M, Arnott, David, Zhu, Yuda, Haznedar, Joshua, Kaur, Surinder, Mathews, W Rodney, Honigberg, Lee A
Publicado 2014

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

por Monteiro, Cecilia, Toth, Balazs, Brunstein, Flavia, Bobbala, Ashwini, Datta, Seema, Ceniceros, Ryan, Sanabria Bohorquez, Sandra M., Anania, Veronica G., Wildsmith, Kristin R., Schauer, Stephen P., Lee, Julie, Dolton, Michael J., Ramakrishnan, Vidya, Abramzon, Daniel, Teng, Edmond
Publicado 2023

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mil...

por Salloway, Stephen, Honigberg, Lee A., Cho, William, Ward, Michael, Friesenhahn, Michel, Brunstein, Flavia, Quartino, Angelica, Clayton, David, Mortensen, Deborah, Bittner, Tobias, Ho, Carole, Rabe, Christina, Schauer, Stephen P., Wildsmith, Kristin R., Fuji, Reina N., Suliman, Shehnaaz, Reiman, Eric M., Chen, Kewei, Paul, Robert
Publicado 2018